TVRD SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Core Insights - Tvardi Therapeutics, Inc. experienced a significant stock decline of over 80% following disappointing preliminary data from its Phase 2 REVERT clinical trial for TTI-101 in idiopathic pulmonary fibrosis [5]. Company Overview - Tvardi Therapeutics, Inc. is currently under investigation by Faruqi & Faruqi, LLP for potential claims related to the significant losses suffered by investors [4]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4]. Clinical Trial Details - The Phase 2 REVERT clinical trial aimed to evaluate the safety, pharmacokinetics, and exploratory outcomes related to lung function of TTI-101 [5]. - Preliminary data indicated that the trial did not meet its goals, with safety data and exploratory efficacy results showing no significant improvement in lung function as measured by Forced Vital Capacity (FVC) [5]. - The baseline characteristics of patients were similar across treatment arms, except for a lower percent predicted FVC in the placebo group compared to the TTI-101 group [5].